Steen S N, Smith R, Kuo J, Ziment I, Beall G N
Chest. 1977 Dec;72(6):724-30. doi: 10.1378/chest.72.6.724.
Aerosolized fenoterol in a dosage of 400 microgram was compared to isoproterenol 150 microgram in 31 asthmatic subjects during the course of a double-blind parallel 90-day study. Bronchodilator activities of the two drugs were evaluated for up to 6 hours on days 1, 45 and 90. Analysis of the data revealed that fenoterol consistently produced a significantly greater increase in FEV1, FEF25-75% and Gaw/VL. Specific airway conductance increased on each test day 25 percent or more above baseline for over three hours after use of fenoterol and for only one hour after use of isoproterenol. Fenoterol has less effect upon the cardiovascular and central nervous systems, but produced a greater incidence of shaking compared to isoproterenol. Patients used fenoterol less frequently than isoproterenol which can be attributed to the former having a greater peak effect and time course of bronchodilation. The therapeutic efficacy of fenoterol was sustained throughout this three-month study, and suggests that this relatively selective beta2 adrenergic drug will provide a well tolerated, alternative aerosol for chronic use in asthma.
在一项为期90天的双盲平行研究中，对31名哮喘患者比较了剂量为400微克的雾化非诺特罗与150微克异丙肾上腺素的效果。在第1天、第45天和第90天评估了两种药物长达6小时的支气管扩张活性。数据分析显示，非诺特罗持续使第一秒用力呼气容积（FEV1）、用力呼气中期流速（FEF25-75%）和比气道传导率（Gaw/VL）显著增加。使用非诺特罗后，在每个测试日，特定气道传导率在高于基线水平25%或更多的情况下持续超过三小时，而使用异丙肾上腺素后仅持续一小时。非诺特罗对心血管和中枢神经系统的影响较小，但与异丙肾上腺素相比，震颤发生率更高。患者使用非诺特罗的频率低于异丙肾上腺素，这可归因于前者具有更大的支气管扩张峰值效应和作用时间过程。在这项为期三个月的研究中，非诺特罗的治疗效果持续存在，这表明这种相对选择性的β2肾上腺素能药物将为哮喘的慢性治疗提供一种耐受性良好的替代气雾剂。
